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Background: Low adherence to pharmacological treatments is one of the factors associated 
with poor blood pressure control. Questionnaires are an indirect measurement method that 
is both economic and easy to use. However, questionnaires should meet specific criteria, to 
minimize error and ensure reproducibility of results. Numerous studies have been conducted to 
design questionnaires that quantify adherence to pharmacological antihypertensive treatments. 
Nevertheless, it is unknown whether questionnaires fulfil the minimum requirements of validity 
and reliability. The aim of this study was to compile validated questionnaires measuring 
adherence to pharmacological antihypertensive treatments that had at least one measure of 
validity and one measure of reliability.
Methods: A literature search was undertaken in PubMed, the Excerpta Medica Database 
(EMBASE), and the Latin American and Caribbean Health Sciences Literature database 
(Literatura Latino-Americana e do Caribe em Ciências da Saúde [LILACS]). References from 
included articles were hand-searched. The included papers were all that were published in 
English, French, Portuguese, and Spanish from the beginning of the database’s indexing until 
July 8, 2013, where a validation of a questionnaire (at least one demonstration of the valid-
ity and at least one of reliability) was performed to measure adherence to antihypertensive 
pharmacological treatments.
Results: A total of 234 potential papers were identified in the electronic database search; of 
these, 12 met the eligibility criteria. Within these 12 papers, six questionnaires were validated: 
the Morisky–Green–Levine; Brief Medication Questionnaire; Hill-Bone Compliance to High 
Blood Pressure Therapy Scale; Morisky Medication Adherence Scale; Treatment Adherence 
Questionnaire for Patients with Hypertension (TAQPH); and Martín–Bayarre–Grau. Question-
naire length ranged from four to 28 items. Internal consistency, assessed by Cronbach’s α, 
varied from 0.43 to 0.889. Additional statistical techniques utilized to assess the psychometric 
properties of the questionnaires varied greatly across studies.
Conclusion: At this stage, none of the six questionnaires included could be considered a gold 
standard. However, this revision will assist health professionals in the selection of the most 
appropriate tool for their individual circumstances.
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Introduction
Hypertension is a major public health concern worldwide. It is one of the leading 
risk factors for cardiovascular disease and is associated with a decrease in a patient’s 
quality of life and an increase in the probability of health complications.1 An estimated 
14% of all deaths worldwide are attributable to high blood pressure (systolic blood 
pressure 140 mmHg; diastolic blood pressure 90 mmHg).2 In Spain, 54% of 
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cardiovascular-related deaths in people older than 50 years 
are due to hypertension.3
It is widely accepted that there are relationships between 
poor blood pressure control and a patient’s lack of adherence 
to antihypertensive treatment, as well as lack of effectiveness 
to antihypertensive treatments.4–8 Research has been con-
ducted in an attempt to reduce nonadherence.6,8,9 In spite of 
this, a study showed the mean prevalence of nonadherence 
to antihypertensive treatments to be 30%.10
Several terms are found in biomedical literature to explain 
the degree to which patients follow prescribed medication 
directions, including the terms “adherence” and “compli-
ance”. Haynes et al defined “compliance” in 1979 as the extent 
to which a person’s behavior (in terms of taking medications, 
following diets or executing lifestyle changes) coincides with 
medical care or health advice; thus, noncompliance is the 
extent to which these instructions are not accomplished.11 The 
World Health Organization (WHO) combined the definitions 
developed by Haynes et al with one by Rand12 to obtain their 
definition of adherence to long-term treatment as 
the extent to which a person’s behavior (in terms of taking 
medications, following diets or executing lifestyle changes) 
corresponds to the recommendations agreed by a health 
care provider.13
Later, Osterberg and Blaschke stated the term “adher ence” 
… is preferred by many health care providers, because 
compliance suggests that the patient is passively following 
the doctor’s orders and that the treatment plan is not based 
on a therapeutic alliance or contract established between 
the patient and the physician.14
Regardless of the definition used, health discipline, or 
health problem, measuring adherence has been complicated. 
Both direct (biological measures) and indirect (pill counts, 
patient-kept diaries of medication-taking, and questionnaires) 
methods have been used.14,15 Biological measures are consid-
ered a gold standard due to their objectivity, but their high 
cost is prohibitive. On the other hand, pill counts are simple, 
but they do not guarantee patient collaboration, and as such, 
results of pill counts may be inaccurate. Questionnaires are an 
alternative. Even though questionnaires have the disadvantage 
of overestimating patient adherence or nonadherence,14 their 
advantage is they are easy to use and are relatively inexpen-
sive.16 Moreover, questionnaires are the most common method 
used in clinical settings because they have the ability to pro-
vide information about a patient’s reasons for not adhering 
to prescribed treatments.14 A number of scales of adherence 
to antihypertensive medication have been  developed, but a 
questionnaire considered to be a gold standard does not exist. 
The most widely used17–20 questionnaire is that designed by 
Morisky–Green–Levine (MGL)21 in 1986. This is a unidi-
mensional questionnaire containing four items.
In order to be a useful tool, a questionnaire must be valid 
and reliable.22 Scale validity refers to
the degree of confidence we can have that the measurement 
corresponds to the reality of the phenomenon that is being 
measured,23
that is,
the degree to which an instrument measures what it is sup-
posed to measure.24
Whereas reliability is
the extent to which a measure yields the same number or 
score each time it is administered when the construct being 
measured has not changed.25
A number of questionnaires used in daily clinical practice 
do not reach the minimum standards for validity and reli-
ability.26 Given this, it is necessary to compile an exhaustive 
list of the available validated tools measuring adherence to 
pharmacological antihypertensive treatment.
The aim of this work was to compile the questionnaires 
designed to measure adherence to pharmacological antihy-
pertensive treatment that have at least one test of validity 
and one test of reliability.
Materials and methods
A literature search was undertaken in three electronic 
databases: US National Library of Medicine (PubMed), 
Excerpta Medica Database (EMBASE), and the Latin 
American and Caribbean Health Sciences Literature 
database (Literatura Latino-Americana e do Caribe em 
Ciências da Saúde [LILACS]). The search terms were: 
“patient adherence”, “patient compliance [Medical 
Subject Headings {MeSH}]”, “compliance”, “predic-
tive validity”, “content validity”, “concurrent validity”, 
“convergent validity”, “discriminant validity”, “con-
struct validity”, “psychometric properties”, “clinimetric 
properties”, “test-retest reliability”, “temporal stability”, 
“interobserver agreement”, “internal homogeneity”, 
“internal consistency”, “questionnaires [MeSH]”, 
“reproducibility of results [MeSH]”, “cronbach’s alpha”, 
and “hypertension [MeSH]”. Keywords were truncated in 
the LILACS database to avoid the loss of papers that could 
be of interest. In addition, the search was complemented 
by reference lists from the included papers.
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inclusion criteria
Articles needed to include the validation of a question-
naire to measure patient adherence to pharmacological 
antihypertensive treatments, published from the begin-
ning of the database’s indexing until July 8, 2013. The 
articles had to include at least one validity test (content-, 
construct-, or criterion-related) and one reliability test 
(stability, equivalence, or homogeneity) of the question-
naire. Language limits were English, Spanish, French, and 
Portuguese.
Article selection
Duplications were removed. Two independent authors read 
the titles and abstracts to select the articles that met the 
inclusion criteria. If doubts appeared, the whole article was 
read. If there was disagreement, a third author arbitrated the 
debate between the two first authors.
Data extraction
Two authors extracted data independently. These data referred 
to the characteristics of the studied population and to the psycho-
metric properties of the questionnaire being tested.26 Afterwards, 
extracted data was checked for any disagreement. When there 
was disagreement, the third author resolved the conflict.
Results
A total 234 articles were retrieved. Three were not available. 
From the remaining 231, 52 were duplicated. Of these,104 
articles were removed by title, 46 by abstract, and finally, 
17 were removed after reading the whole article. Ultimately 
12 articles were included in the revision (Figure 1).
Articles were removed if they did not meet the inclusion 
criteria, that is, they did not validate a questionnaire for 
measuring adherence to antihypertensive treatments or dem-
onstrate the required psychometric properties. For example, 
Figure 1 Flow of information through the different phases of the systematic review.
Abbreviations: eMBASe, excerpta Medica Database; LiLACS, Literatura Latino Americana e do Caribe em Ciências da Saúde (Latin American and Caribbean Health 
Sciences Literature).





some articles did not measure treatment adherence but rather, 
reported the patients’ understanding about hypertension treat-
ment, while others measured quality of life in hypertensive 
patients, patient knowledge about the disease, or patient 
satisfaction with their medication. Furthermore, there were 
articles that measured adherence in diseases other than 
hypertension and in other fields, such as nutrition. Articles 
in which adherence was the subject but measured related 
factors (aptitudes, beliefs, etc) instead of classifying patients 
as adherent or nonadherent, were similarly eliminated.
The 12 articles selected included 15 validation pro-
cesses for six questionnaires that measured adherence to 
pharmacological antihypertensive treatments (Table 1). The 
questionnaires were the following:
– MGL (two validations)21,27
– Brief Medication Questionnaire (BMQ) (one 
validation)27
– Hill-Bone Compliance to High Blood Pressure 
Therapy Scale (HB Comp Scale) (six validat ions)7,28–30
– Morisky Medication Adherence Scale (MMAS-8) 
(three validations)31–33
– Treatment Adherence Questionnaire for Patients with 
Hypertension (TAQPH) (one validation)34
– Martín–Bayarre–Grau (MBG) (two validations).35,36
Content validity
Content validity was assessed in four questionnaires: HB Comp 
Scale,28 TAQPH,34 MMAS-8 (Urdu version), 31 and MBG 
(validated in Cuba).35 In all four validation studies, the authors 
used an expert panel. In addition, for item generation, two ques-
tionnaires (HB Comp Scale and TAQPH) included a narrative 
review, and one (TAQPH) performed a focus group.
Construct validity 
Construct validity was assessed in eleven of 15 validation 
processes (Table 2). The Urdu version of the MMAS-833 
evaluated both convergent validity, by comparing the results 
to the MGL,21 and known group validity, comparing the results 
of the questionnaire to blood pressure control. The remaining 
construct validity assessments were performed by factor anal-
ysis. In the MGL,21 HB Comp Scale,28 Hill-Bone Medication 
Adherence-Korean version (HBMA-K) scale (a validation of 
HB Comp Scale),30 and MMAS-8 (English32 and French31 ver-
sions) the factor analysis yielded a one-dimensional solution. 
On the other hand, the TAQPH34 questionnaire yielded six 
factors, and the Colombian MBG36 yielded five.
Total variance ranged from 68.7%, in the MBG validated 
in Cuba,35 to 27%, in the HB Comp Scale validated in young 
African American males.28
Table 1 Characteristics of the articles included
Author,  
year of publication
Questionnaire Mean  
age (SD)
Sex %  
female, (n)
Language Setting Sample (n) Items
Morisky et al21 1986 MGL 54a 70.00 (–) english Hospital  
(outpatient clinics)
290 4




Kim et al28 2000 HB Comp Scale 41.30 (5.30) 0.00 (0) english Outpatient clinic Study 1: 139 14
59.20 (13.10) 69.20 (236) Study 2: 341
Krousel-wood et al7 2005 HB Comp Scale 
(elderly)
69.00 (–) 49.00 (121) english elderly community-
dwelling
239 14
Lambert et al29 2006 Xhosa HB Comp Scale 52.00 (7.60) 51.00 (50) Xhosa Community  
health centers
79 14
Xhosa Adapted HB 
Comp Scale
82 10
Song et al30 2011 HBMA-K 52.54 (5.40) 56.80 (88) Korean Baltimore-  
washington 
metropolitan area
Study 1: 155 8
70.88 (5.40) 70.50 (261) Study 2: 370
Morisky et al32 2008 MMAS-8 52.50 (12.20) 59.20 (809) english Hospital 1,367 8
Korb-Savoldelli et al31 2012 MMAS-8 55.70 (14.60) 42.70 (85) French Hospital, day  
care unit
199 8
Saleem et al33 2012 MMAS-8 39.50 (6.93) 28.20 (31) Urdu Hospital 110 8
Ma et al34 2012 TAQPH 59.68 (10.69) 58.30 (162) Chinese Hospital 278 28
Martín Alfonso et al35 2008 MBG – – Spanish Polyclinic 114 12
Martínez et al36 2011 MBG Not indicatedb 81.00 (115) Spanish Health care center 142 12
Notes: aMedian. bRange 37–90 years.
Abbreviations: BMQ, Brief Medication Questionnaire; HB Comp Scale, Hill-Bone Compliance to High Blood Pressure Therapy Scale; HBMA-K, Hill-Bone Medication 
Adherence – Korean version scale; MBG, Martín–Bayarre–Grau; MGL, Morisky–Green–Levine; MMAS-8, Morisky Medication Adherence Scale; SD, standard deviation; 
TAQPH, Treatment Adherence Questionnaire for Patients with Hypertension.
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Criterion validity
Four validations (MGL,21 HBMA-K,30 MMAS-832 (English), 
and TAQPH34) assessed concurrent validity, and six evalu-
ated predictive validity (MGL,21 Xhosa HB Comp Scale,29 
HB Comp Scale28 [two validations], and the MMAS-832 
[English]). The comparison tests are detailed in Table 2.
Reliability
Cronbach’s α was used to estimate internal consistency as a 
reliability measure in every validation. The MBG validated 
in Cuba35 obtained the highest coefficient (α=0.889), while 
the lowest (α=0.43) was obtained in the HB Comp Scale7 
validated in an elderly population, published by Krousel-
Wood et al. Item-total scale correlation was also used in all 
but three validations (Table 2).
The MMAS scale in Urdu33 and French,31 the TAQPH,34 
and the BMQ27 evaluated temporal stability with the test–
retest method. In each of these validations, temporal stability 
was demonstrated with a moderate to high correlation, except 
for the TAQPH34 questionnaire, which had an intraclass cor-
relation coefficient of 0.82.
Discussion
This review provides health professionals with a report 
summarizing the evidence across different questionnaires 
according to the psychometric properties evaluated. 
The review did not intend to determine or indicate an 
optimum questionnaire but rather, to compile validated 
scales that measure antihypertensive treatment adher-
ence. Consequently, health professionals can choose 
the most appropriate questionnaire, depending on their 
circumstances. To our knowledge there is no similar 
published study.
A large number of authors have designed questionnaires 
in order to measure adherence to antihypertensive treatments. 
Nevertheless, no questionnaire could be considered a gold 
standard. Any tool to be used as a measure must demon-
strate validity and reliability, including questionnaires.22 
Furthermore, validity and reliability must be measured in 
each sample or have been conducted in a comparable sample 
since it is not possible to extrapolate results among different 
populations. Differences in validity and reliability results 
obtained across versions of the MMAS-831–33 can be seen 
as an example.
A sensitive search strategy was designed to ensure the 
collection of all papers validating questionnaires to measure 
adherence to pharmacological antihypertensive treatment. 
Inclusion criteria in this review required that articles have 
at least one validity test and one of reliability. Taking into 
account these criteria, such well-known questionnaires as the 
BMQ (English version),44 the Haynes–Sackett11 and Batalla 
questionnaires,45 etc were not included.
The validity of a questionnaire (the confirmation that 
it measures what it is supposed to measure) is evaluated in 
several ways, as: content validity, construct validity, and 
criterion validity.
The methods most commonly used to assess content 
validity are expert opinion and systematic review. However, 
researchers often choose only one of these options. From the 
15 validations found, only four studied content validity, and 
even these did not explain in detail the process followed to 
assess it. It is suspected that in the remaining questionnaires, 
authors assumed, without testing, content validity was 
present. In the four validations that assessed content valid-
ity, the technique utilized was an expert panel. None of the 
authors based content validity on a systematic review. This 
method could be of great interest, but it can increase costs 
and research time.
The most common technique to assess construct validity 
was factor analysis. A one-dimensional solution emerged 
in the majority of the scales, but the factor explained only 
a small percentage of the total response variability. As an 
example, the HB Comp Scale28 and the HBMA-K30 explained 
up to 35% of the total variance. Consequently questionnaires 
should consider including further dimensions and items 
to explain more of the total response variance. This could 
be observed in the TAQPH,34 which had 28 items and six 
factors, and was able to explain 62.5% of the variance. The 
total explained variance is considered an indicator of how 
factors extracted from a questionnaire actually correspond to 
patient answers. When little variance is explained, the scale 
shows a deficiency that indicates lack of variables or a poor 
initial theoretical construct. However, it is also important that 
a questionnaire does not have too many items, to minimize 
patient resistance to being interviewed and interview 
duration. As such, the number of items needs to be balanced 
between explaining variance and user acceptance.
Construct validity assessment by convergent validity was 
completed in two questionnaires. The correlation between 
the Urdu version of the MMAS-833 and the same language 
version of the MGL21 was checked. A high correlation was 
found between the scales (ρ=0.765, P0.001), which in 
theory confirmed that both questionnaires measured the same 
construct. However such a correlation is not surprising as the 
MMAS-8 was based on the MGL four-item questionnaire, 
onto which more questions were added.32





Criterion validity is traditionally defined as 
the correlation of a scale with some other measure of the 
trait or disorder under study, ideally a gold standard which 
has been used and accepted in the field.46
Criterion validity consists of two types: concurrent and 
predictive. In concurrent validity, both the new scale and 
a criterion measure are applied simultaneously and subse-
quently correlated. On the other hand, when using predictive 
validity, the criterion measure will not be available until 
sometime in the future. This implies that testing predictive 
validity may extend the time of study.
With the exception of six validations, the remainder tested 
criterion validity. The validation of HBMA-K30 obtained a 
low correlation to systolic blood pressure control (r=0.18; 
P0.01) and diastolic blood pressure (r=0.24; P0.01). 
This low correlation could be due to the fact that medication 
adherence is not perfectly correlated to blood pressure control. 
That is, it is possible for a patient to have high medication 
adherence and to not have controlled blood pressure due to 
another factor, such as lack of effectiveness of the treatment. 
Nevertheless, it is assumed that there is a direct relationship 
between adherence and blood pressure control.47 On the other 
hand, the MMAS-8,32 compared with the MGL21 to assess 
concurrent validity, obtained a moderate to high correlation 
(r=0.64; P0.05). It is necessary to keep in mind that the 
development of the MMAS-8 was based on the MGL, as 
stated previously.
In addition to verifying the validity of a questionnaire, it 
is necessary to check the results are reproducible. That is, it 
is necessary to assess its reliability. From a technical point 
of view, it could be said that reliability is 
a ratio of the variability between individuals to the total 
variability in the scores; in other words, the reliability is a 
measure of the proportion of the variability in scores which 
was due to true differences between individuals.46
One of the methods used to measure reliability is internal 
consistency. Internal consistency describes reliability estima-
tions based on the average correlation among items in a test.46 
A Cronbach’s α value is considered acceptable when above 
0.70.48 Only two validations obtained Cronbach’s α values 
well below 0.70 (the HB Comp Scale [elderly]7 [0.43] and 
MMAS-8 [French]31 [0.54]), indicating the items were not 
highly related. In the remaining questionnaires, Cronbach’s α 
varied from 0.61 (in the MGL)21 to 0.889 (in the MGB).35 
However, it should be noted that Cronbach’s α is sensitive 
to the number of items and the sample’s variance.
Cronbach’s α is assessed from a single administra-
tion of the test, not taking into account variations in time 
or between administrators, and as such, it can provide an 
optimistic interpretation of the reliability of a questionnaire. 
For this reason, it is advisable that internal consistency 
is accompanied by a stability measure (test–retest) or by 
interobserver equivalence.46 In the present study, six valida-
tions provided stability data and none checked interobserver 
verifications.
As previously stated, the intent of this article was to 
gather all questionnaires measuring patient adherence to 
antihypertensive treatments that contain at least one validity 
measure and one reliability measure. Furthermore the 
authors do not consider any of the questionnaires to have 
sufficient reliability or validity to be highly recommended. 
Nevertheless, if one had to choose a questionnaire, the 
authors offer these considerations.
For research, the TAQPH may be advisable. The 
TAQPH contains the greatest number of items, potentially 
providing more information to the research investigation, 
explains a high percentage of variance, and has sound 
indicators for both stability and criterion validity. The 
MBG also contains a large number of items but cannot be 
endorsed as it lacks criterion validity, stability, and item-
total correlations.
In clinical practice it is necessary that a questionnaire 
is acceptable to both health care professionals and patients 
(containing the fewest possible items), is quick and easy to 
use, and shows good sensitivity, specificity, positive predic-
tive value, and negative predictive value. The MGL, BMQ, 
HB Comp Scale, and MMAS-8 have similar indicators of 
reliability and validity; however, only the MMAS-8 and 
MGL show the probability of a clinician deciding that a non-
adherent patient is not controlled (positive predictive value) 
or that an adherent patient is controlled (negative predictive 
value). As such, in clinical practice, both the MMAS-8 and 
MGL may be recommended. However as previously noted, 
the MMAS-8 was developed by Morisky et al in 200832 based 
on the MGL and as such, has an improved capacity to collect 
information (by having four additional items), sensitivity, 
specificity, positive predictive value, and negative predictive 
value, while maintaining acceptable validity and reliability. 
Consequently in clinical practice, the MMAS-8 may be an 
appealing option.
Limitations
This study could be influenced by publication bias as a conse-
quence of the general tendency to publish only positive results. 
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Language bias could also have appeared. In spite of including 
studies published in four languages, it is possible that some 
studies were not included because of being published in other 
languages. Moreover, despite the strict methodology followed 
by reviewers, it is possible that selection bias appeared as a 
consequence of the lack of availability of some articles.
Conclusion
This review provides information of great relevance to daily 
clinical practice. In spite of the number of studies performed 
to measure adherence, not all of the questionnaires used in 
the studies reach the requirements to be considered valid 
and reliable tools. Six questionnaires were identified to 
measure adherence to pharmacological antihypertensive 
treatment that had at least one validity test and one test of 
reliability. While some of these questionnaires had evidence 
to demonstrate acceptable validity, they failed in reliability 
and vice versa. Therefore although none of the questionnaires 
can be considered as a gold standard, this revision will assist 
health professionals in the selection of the most appropriate 
tool, depending on their circumstances. In the future, the 
design and validation of a questionnaire to measure adher-
ence to antihypertensive treatments reaching the following 
requirements is fundamental: a) to be succinct enough to 
avoid patient and/or administrator fatigue (acceptability) but 
comprehensive enough to explain variance; b) include explicit 
content validity, have construct validity in accordance with a 
logical and reasoned theoretical structure that justifies items 
and subscales, and/or demonstrate criterion validity and; c) 
be a tool that provides reproducible results (reliable).
Disclosure
The authors report no conflicts of interest in this work.
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